Azenta Inc (AZTA)vsMedline Inc. Class A Common Stock (MDLN)
AZTA
Azenta Inc
$21.86
+2.58%
HEALTHCARE · Cap: $1.01B
MDLN
Medline Inc. Class A Common Stock
$42.67
+1.52%
HEALTHCARE · Cap: $34.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 4678% more annual revenue ($28.43B vs $595.03M). MDLN leads profitability with a 4.1% profit margin vs -10.1%. MDLN trades at a lower P/E of 29.9x. AZTA earns a higher WallStSmart Score of 57/100 (C).
AZTA
Buy57
out of 100
Grade: C
MDLN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-12.2%
Fair Value
$27.14
Current Price
$21.86
$5.28 premium
Margin of Safety
+32.7%
Fair Value
$66.92
Current Price
$42.67
$24.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 80.0% year-over-year
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 1.5% — below average capital efficiency
Currently unprofitable
Moderate valuation
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 80.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : MDLN
Revenue growth of 14.8% demonstrates continued momentum.
Bear Case : AZTA
The primary concerns for AZTA are P/E Ratio, Market Cap, Return on Equity.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZTA profiles as a hypergrowth stock while MDLN is a value play — different risk/reward profiles.
AZTA is growing revenue faster at 80.0% — sustainability is the question.
AZTA generates stronger free cash flow (15M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZTA scores higher overall (57/100 vs 52/100) and 80.0% revenue growth. MDLN offers better value entry with a 32.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a leading provider of sample management solutions and life science tools, specializing in enhancing laboratory efficiencies for the biotechnology and pharmaceutical sectors. Leveraging innovative automated solutions, biorepository services, and advanced storage technologies, the company empowers clients to accelerate drug discovery while maintaining strict regulatory compliance. With a strong focus on cutting-edge technology and collaborative partnerships, Azenta is strategically positioned to capitalize on growth opportunities within the expanding global life sciences market. Its unwavering commitment to advancing scientific research through sophisticated products further reinforces its competitive edge in biobanking and sample management.
Visit Website →Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?